Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
Arimidex, Tamoxifen, Alone or in Combination Trialists' Group; Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM. Arimidex, Tamoxifen, Alone or in Combination Trialists' Group, et al. Among authors: locker gy. Lancet Oncol. 2006 Aug;7(8):633-43. doi: 10.1016/S1470-2045(06)70767-7. Lancet Oncol. 2006. PMID: 16887480 Clinical Trial.
Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
Locker GY, Mansel R, Cella D, Dobrez D, Sorensen S, Gandhi SK; ATAC Trialists' Group. Locker GY, et al. Breast Cancer Res Treat. 2007 Dec;106(2):229-38. doi: 10.1007/s10549-006-9483-6. Epub 2007 Jan 24. Breast Cancer Res Treat. 2007. PMID: 17245540
Adjuvant use of anastrozole in breast cancer.
Cuzick J, Buzdar A, Baum M, Bianco R, Coleman R, Constenla M, Distler W, Dowsett M, Forbes J, Guastalla JP, Houghton J, Williams N, Howell A, Locker G, MacKey J, Sainsbury R, Tobias J. Cuzick J, et al. J Clin Oncol. 2004 Apr 15;22(8):1524-6; author reply 1526-7. doi: 10.1200/JCO.2004.99.165. J Clin Oncol. 2004. PMID: 15084628 No abstract available.
Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial.
Mansel R, Locker G, Fallowfield L, Benedict A, Jones D. Mansel R, et al. Br J Cancer. 2007 Jul 16;97(2):152-61. doi: 10.1038/sj.bjc.6603804. Epub 2007 Jul 10. Br J Cancer. 2007. PMID: 17622238 Free PMC article. Clinical Trial.
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, Shen L, Qin S, Xu N, Im SA, Locker G, Rowe P, Shi X, Hodgson D, Liu YZ, Boku N. Bang YJ, et al. Lancet Oncol. 2017 Dec;18(12):1637-1651. doi: 10.1016/S1470-2045(17)30682-4. Epub 2017 Nov 2. Lancet Oncol. 2017. PMID: 29103871 Clinical Trial.
57 results